Inhibikase Therapeutics Inc (IKT) Directors and Executive Officers

Officers & Directors

DENNIS BERMAN
Director

JOSEPH FRATTAROLI
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

MILTON H. WERNER, Ph.D.
Chief Executive Officer and Director (Principal Executive Officer)

ROY FREEMAN, M.D.
Director

PAUL GRINT, M.D.
Director

GISELE DION
Director

CohnRenzick LLP
Auditor ,

Inhibikase Therapeutics Inc currently has 35 employees.

News about Inhibikase Therapeutics Inc Key Personnel

Inhibikase Therapeutics Strengthens Leadership with New CFO Amid Financial Challenges and Promising Growth in PAH Research,

Navigating Challenges and Opportunities: Inhibikase Therapeutics Leadership Expansion Amid Financial DynamicsInhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company focused on innovative small molecule kinase inhibitor therapeutics for pulmonary arterial hypertension (PAH), has made significant strides recently by appointing David McIntyre as Chief Financial Officer, effective April 14, 2025. This move comes as part of a broader strategy to bolster the company s leadership team amidst notable financial milestones and the pursuit of advancing critical therapeutic developments.Despite a challenging financial climate, highlighted by a cumulative net loss of $-28 million during the...

Inhibikase Therapeutics Expands Leadership Team with New Appointments Amidst $110 Million Funding for PAH Trials,

Inhibikase Therapeutics Expands Leadership Team Amid Significant Financial MilestonesIn an important strategic move, Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced the expansion of its senior leadership team, appointing two distinguished professionals who bring a wealth of experience and expertise instrumental in advancing the company’s innovative therapeutic developments. Dr. Chris Cabell has been appointed as President and Head of Research and Development, while Dr. John Adams takes on the role of Chief Scientific Officer. This leadership expansion comes at a time when Inhibikase is experiencing notable financial dynamics and active efforts toward groundbreaking research in the realm of cardiopulm...